Cingulate Inc.
NASDAQ:CINGBiotechnology
-$0.05 today
- Market cap
- $76.46M
- Beta
- -0.91
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$5.10
Volume 0.95M
Average 0.46M
CING Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Cingulate Inc.NASDAQ: CING
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures turns negative
Q1 FY2026 capital expenditures was -$61.18K, compared with $2 a year earlier. Trailing-twelve-month capital expenditures was -$223.31K. Over 3 fiscal years it compounded at +1.9% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly capital expenditures holds near -$61.18K or moves back toward the trailing-twelve-month quarterly average of -$55.83K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (162.14K) USD
- Year-over-year change
- +23.4%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (162.14K) | +23.4% |
| FY2024 | 2024-12-31 | (211.8K) | +5.5% |
| FY2023 | 2023-12-31 | (224.1K) | -46.1% |
| FY2022 | 2022-12-31 | (153.42K) | +81.2% |
| FY2021 | 2021-12-31 | (814.74K) | — |
Capital Expenditures vs competitors
How CING compares with its peers on the latest reported figures
- CING's LTM Mar 2026 capital expenditures of $223.31K is the largest of the 2 companies compared; the peer median is $24.85K.
- Its year-over-year change of +71.4% is the lowest of 2, against a peer median of +1242500.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $223.31K | +71.4% | +1.9% | — | |
| LTM Mar 2026 | $24.85K | +1242500.0% | — | — | |
| Peer median (excluding CING) | $24.85K | +1242500.0% | — | — | |
Competitors are the stored peer set for CING. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.71M) | (17.68M) | (23.53M) | (15.55M) | (22.45M) |
| Depreciation & Amortization | 708.32K | 394.01K | 582.92K | 653.09K | 540.89K |
| Deferred Income Tax | (16.26M) | (797.96K) | 0 | 0 | 0 |
| Stock-Based Compensation | 12.78M | 800.8K | 812.67K | 995.48K | 0 |
| Change in Working Capital | (3.21M) | 598.62K | 7.1M | (4.55M) | 830.85K |
| Accounts Receivables | (1.86M) | 1.25M | 219.81K | (11.7K) | 18.31K |
| Inventory | 0 | (1.25M) | 0 | 0 | 0 |
| Accounts Payables | 0 | 791.01K | 0 | 0 | 0 |
| Other Working Capital | (1.35M) | (192.39K) | 6.89M | (4.54M) | 812.54K |
| Other Non-Cash Items | 16.26M | 797.96K | 0 | 0 | 3.83M |
| Operating Cash Flow | (10.43M) | (15.88M) | (15.03M) | (18.45M) | (17.25M) |
| Capital Expenditures | (814.74K) | (153.42K) | (224.1K) | (211.8K) | (162.14K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 933 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (165) | 0 | 0 | 138 |
| Investing Cash Flow | (814.74K) | (152.65K) | (224.1K) | (211.8K) | (162K) |
| Debt Repayment | (936.59K) | 4.98M | 2.98M | 4.95M | 6M |
| Common Stock Issued | 20.37M | (85.92K) | 6.97M | 25.88M | 10.15M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.1M | 0 | 0 | 0 | (382) |
| Financing Cash Flow | 26.54M | 4.9M | 9.95M | 30.82M | 16.15M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 15.3M | (11.14M) | (5.3M) | 12.16M | (1.26M) |
| Free Cash Flow | (11.25M) | (16.04M) | (15.26M) | (18.66M) | (17.41M) |
Cingulate Inc.
NASDAQ:CING
Intrinsic Alpha fair value
Locked
Current Price
$5.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.